- **Title:** *Plasmodium falciparum multidrug resistance 1* gene polymorphisms associated with 1
- 2 outcomes after antimalarial treatment
- 3 Running title: Pfmdr1 and malaria outcomes
- Veronika R. Laird^{1,2,3}, Mateusz M. Plucinski², Meera Venkatesan⁴, Kelsey A. Rondini^{2,5}, 4
- Milijaona Randrianarivelojosia^{6,7}, Mauricette N. Andriamananjara⁸, Hawela Moonga⁹, Deus S. 5
- 6
- 7
- Ishengoma¹⁰, Arlindo Chidimatembue¹¹, Pedro Rafael Dimbu¹², Adicatou-Laï Adeothy¹³, Abdoul Habib Beavogui¹⁴, Simon Kariuki¹⁵, Sam L. Nsobya¹⁶, Aline Uwimana¹⁷, Gauthier Mesia Kahunu^{18,19}, Ashenafi Assefa²⁰, Ousmane A. Koita²¹, Naomi W. Lucchi^{22,23}, Samaly S. 8
- Svigel Souza²³, Zhiyong Zhou²³ Leah F. Moriarty², Eric S. Halsey² 9
- 10
- Article word count (Introduction through Discussion): 3,488 11
- 12 **Corresponding author:**
- Veronika R. Laird 13
- 14 2006 E Lombard
- 15 Baltimore, MD
- 16 21231
- 17 **USA**
- 18
- 19 veronika.laird97@gmail.com
- 20
- Alternate corresponding author: 21
- 22 Eric Halsey
- 1600 Clifton Road 23
- 24 Mail Stop: H16-4
- Atlanta, GA 30329 25
- 26 USA
- 27

Affiliations: 28

- ¹Department of Epidemiology, Emory University, Atlanta, GA, USA. 29
- ²US President's Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria, 30
- Centers for Disease Control and Prevention, Atlanta, GA, USA 31
- ³Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, United States 32
- 33 ⁴US President's Malaria Initiative, United States Agency for International Development,
- Washington, DC, USA 34
- ⁵Booz Allen Hamilton, Atlanta, GA, USA 35
- ⁶Institut Pasteur de Madagascar, Antananarivo, Madagascar 36
- ⁷Faculté des Sciences, Université de Toliara, Toliara, Madagascar 37
- ⁸Direction de La Démographie et des Statistiques Sociales, Institut National de La Statistique, 38
- 39 Antananarivo, Madagascar
- ⁹National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia 40
- ¹⁰National Institute for Medical Research, Dar es Salaam, Tanzania 41
- ¹¹Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique 42
- ¹²National Malaria Control Program, Ministry of Health, Luanda, Angola 43
- ¹³National Malaria Control Program, Ministry of Health, Porto-Novo, Benin 44

- ⁴⁵ ¹⁴Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Forecariah,
- 46 Guinea
- ¹⁵Kenya Medical Research Institute (KEMRI)-Centre for Global Health Research, Kisumu,
- 48 Kenya
- 49 ¹⁶ Infectious Diseases Research Collaboration (IDRC), Kampala, Uganda
- ¹⁷Malaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre (RBC), Kigali,
- 51 Rwanda
- ¹⁸Unit of Clinical Pharmacology and Pharmacovigilance University of Kinshasa, Kinshasa,
- 53 Democratic Republic of the Congo
- ¹⁹Department of Pharmacology and Therapeutics, University of Kinshasa, Kinshasa, Democratic
 Republic of the Congo
- ²⁰Ethiopian Public Health Institute, Arbegnoch Street, Addis Ababa, Ethiopia
- ²¹Mali-Tulane Tropical Medicine Research Center, Faculty of Medicine, Pharmacy, and
- 58 Dentistry, University of Bamako, Bamako, Mali
- ²²U.S. President's Malaria Initiative, US Centers for Disease Control and Prevention, Kigali,
- 60 Rwanda
- ²³Malaria Laboratory Research & Development Team, Malaria Branch, U.S. Centers for Disease
- 62 Control and Prevention, Atlanta, GA, USA
- 63

64 **Author contributions**

- 65 Developed the study idea: VL, MP, MV, EH
- Collected the data: MR, MA, HW, DI, AC, PD, AA, AB, SK, SN, AU, GK, AA, OK, NL, SS,
 ZZ
- 68 Analyzed the data: VL, MP, KR, LM, EH
- 69 Wrote the manuscript: VL, MP, EH
- 70 Approved the manuscript: All
- 71

72 Article summary:

- 73 This study suggests that: 1) patients given AL infected with parasites carrying N86 were
- statistically more likely to experience a recurrent infection; 2) patients given ASAQ infected
- vith parasites carrying 86Y were statistically more likely to experience a recurrent infection.

76 Abstract word count: 200

Background. Plasmodium falciparum multidrug resistance transporter 1 (Pfmdr1) gene
mutations are associated with altered response to artemisinin-based combination therapies
(ACTs), particularly those containing the partner drugs lumefantrine and amodiaquine (i.e.,
artemether-lumefantrine [AL] and artesunate-amodiaquine [ASAQ]). Past studies of *Pfmdr1*single nucleotide polymorphisms (SNPs) at codons 86, 184, and 1246 have shown different
responses to AL and ASAQ.

Methods. To determine whether infection with parasites carrying specific *Pfmdr1* SNPs
 leads to increased risk of recurrent parasitemia (recrudescent or new infection), data from 4,129
 samples from 16 therapeutic efficacy studies from 13 African countries between 2013–2019
 were analyzed.

Results. Patients treated with AL and infected with parasites carrying *Pfmdr1* N86 were
 at greater risk of treatment failure than those whose parasites carried 86Y. After treatment with
 ASAQ, individuals infected with parasites that carried *Pfmdr1* 86Y were more likely to

91 experience a recurrent infection.

92 **Conclusions.** Our results support prior studies that suggested: 1) patients given AL and

infected with parasites carrying N86 were more likely to experience a recurrent infection; 2)
 patients given ASAQ and infected with parasites carrying 86Y were more likely to experience

95 recurrent infection. These findings suggest that ACT and *Pfmdr1* genotype may influence

- 96 outcome after *P. falciparum* infection.
- 97 98

Keywords. malaria, Plasmodium falciparum, Africa, antimalarials, drug resistance

99 Introduction

100	The emergence of <i>Plasmodium falciparum</i> resistance to antimalarials poses a challenge
101	to global malaria control efforts. World Health Organization (WHO) Guidelines for Malaria
102	recommend the use of artemisinin-based combination therapy (ACT) to treat uncomplicated P.
103	falciparum infection (1). Three ACTs used in Africa are artemether-lumefantrine (AL),
104	artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP) (2). Although
105	polymerase chain reaction (PCR)-adjusted efficacy for each ACT remains high throughout most
106	regions (3), suboptimal ACT efficacy has been reported in Asia (4) and Africa (5–7).
107	Although ACT resistance has not been demonstrated with any particular Plasmodium
108	falciparum multidrug resistance transporter 1 single nucleotide polymorphism (SNP) or
109	haplotype, certain SNPs may affect response after treatment with ACTs containing lumefantrine
110	or amodiaquine (8,9). Five unique <i>Pfmdr1</i> SNPs, with amino acid changes in codons 86, 184,
111	1034, 1042, and 1246, have been found in various regions of the world (10). N86, 184F, and
112	D1246 SNPs have been found in post-treatment samples of patients who experienced a recurrent
113	infection after AL treatment (9,11,12). Conversely, studies of SNPs in <i>Pfmdr1</i> have suggested
114	that the 86Y and 1246Y mutations may be associated with decreased response to amodiaquine
115	and ASAQ (9,13). Several in vivo studies in sub-Saharan Africa have found evidence of selection
116	for particular <i>Pfmdr1</i> SNPs at codons 86, 184, and 1246 after treatment with AL (9,14,15).
117	Pfmdr1 SNPs present post-treatment in new infections are also important to understand because
118	they may impact the post-treatment prophylactic effect of the partner drug (16). Increased copy
119	number of <i>Pfmdr1</i> due to gene duplications has also been associated with reduced susceptibility
120	to lumefantrine (10,17).

Sample sizes in individual therapeutic efficacy studies (TESs) are typically too small
to statistically power an assessment of the association between parasite genotypes and treatment

123	outcomes (i.e., adequate clinical and parasitological response, recrudescent infection, and new
124	infection). As part of the US President's Malaria Initiative (PMI), the Centers for Disease
125	Control and Prevention (CDC) and the US Agency for International Development provide
126	support to countries in Africa to perform TESs, including molecular characterization of
127	antimalarial-resistance markers, through the Partnership for Antimalarial Resistance Monitoring
128	in Africa (PARMA) network (18). Established in 2015, this endeavor involves laboratory
129	scientists from endemic countries coming to CDC (Atlanta, Georgia, USA) or, starting in 2022,
130	to a partner lab in Africa to receive advanced laboratory training and perform molecular testing
131	for antimalarial-resistance mutations (18). To examine the association between parasite
132	genotypes and treatment outcomes, in vivo antimalarial efficacy and P. falciparum molecular
133	marker data from samples analyzed and collected from 16 TESs conducted in 13 countries in
134	Africa were used. Understanding this association is important for detecting changes in long-term
135	trends of <i>Pfmdr1</i> SNP prevalence in parasite populations as indicators of changing parasite
136	susceptibility to ACT partner drugs, lumefantrine or amodiaquine. This study had two main
137	objectives to untangle the relationship between parasite <i>Pfmdr1</i> -genotypes and treatment
138	outcomes: 1) To assess whether patients infected with parasites carrying specific <i>Pfmdr1</i> SNPs
139	have increased risk of recurrent infection; 2) To investigate preferential selection of specific
140	<i>Pfmdr1</i> SNPs by ACT type.

141 Methods

142 Selection and inclusion of data

Data for this pooled analysis were compiled from 16 individual TESs from 40 sites across
13 sub-Saharan African countries between 2013–2019 (Figure 1, Supplementary Table 1, and
Supplementary Table 2). The studies were all funded by PMI.

146	Patients with symptomatic, parasitologically-confirmed uncomplicated P. falciparum
147	symptomatic infection who presented to health facilities and met standard WHO inclusion
148	criteria were enrolled (Supplementary Table 2) (24). Patients were administered either AL,
149	ASAQ, or DP. After follow-up was complete, parasite genetic sequencing of <i>Pfmdr1</i> was
150	conducted at the CDC Malaria Branch Laboratory in Atlanta, USA. This was conducted as part
151	of a training program through PARMA (18). Eleven TES results have been published alongside
152	molecular results, three TES efficacy results were published separately from the molecular
153	surveillance results, and two results are contained in unpublished country reports (Benin and
154	Zambia) (Supplementary Table 2).
155	
156	Genotyping of Pfmdr1 SNPs and result calling
157	Patients were considered to have a recurrent infection if their sample was found by
158	microscopy to contain asexual forms of <i>P. falciparum</i> starting on day 4 after ACT treatment until
159	the end of the follow-up period (28, 28, and 42 days for AL, ASAQ, and DP, respectively). For
160	study participants with recurrent infection, the recurrent infection sample and its corresponding
161	pre-treatment sample were genotyped to determine whether the recurrent infection was a
162	recrudescent or new infection. This was done using either seven neutral microsatellite
163	markers (TA1, Poly-a, PfPK2, TA109, TA2490, C2M34, and C3M69) over six chromosomes
164	(20,21) or using the fragment length polymorphism of genes merozoite surface protein 1,
165	merozoite surface protein 2, and glutamate-rich protein (msp1, msp2, and glurp) (22).
166	Pfmdr1 codons 86, 184, 1034, 1042, and 1246 were sequenced in parasites collected from
167	enrolled patients who experienced a recurrent infection from each TES and the SNP at each
168	codon was recorded. Each TES sequenced Pfmdr1 codons 86, 184, 1034, 1042, and 1246 for

169 typically 10% of enrolled patients who experienced an adequate clinical and parasitological 170 response except for the Angola (2013, 2017, 2019), Democratic Republic of the Congo, and Uganda TESs. Sanger sequencing was used to determine the genotype of the five *Pfmdr1* SNPs 171 172 in pre-treatment and recurrent infections samples for each study except the 2019 Angola TES, which utilized next generation sequencing. For each SNP, samples were classified as having 173 174 either a single or mixed infection (mixed genotypes) depending on whether heterozygous SNPs 175 (double peaks representing mixed infections) were identified using the heterozygous call plug-in 176 tool in Geneious software package (Biomatters, Inc., San Francisco, CA) with a minor allele 177 threshold of at least 30%. Mixed infections were recorded in each study except for Tanzania. For samples with mixed infections and SNP variations at codons 86, 184 and 1246, each possible 178 haplotype constructed from the observed SNPs was reported for *Pfmdr1*(23). *Pfmdr1* codons 179 180 1034 and 1042 were not included in the statistical analysis because the vast majority exclusively carried the wild-type SNP. 181

Mixed infections at the codons of interest included N and Y at codon 86 (N/Y), Y and F 182 183 at codon 184 (Y/F), and D and Y at codon 1246 (D/Y). For the odds ratio analysis, mixed infections were reclassified to one SNP per codon for each treatment arm. This baseline SNP 184 185 served as the exposure. For patients treated with AL, mixed infections at codon 86 were reclassified as N86; at codon 184 as 184F; and at codon 1246 as D1246. This is because previous 186 studies have found N86, 184F, and D1246 to predominate in patients after AL treatment 187 188 (9,11,12). For patients treated with ASAQ or DP, mixed infections at codon 86 were reclassified 189 as 86Y; at codon 184 as Y184; and at codon 1246 as 1246Y. This is because previous studies have found 86Y, Y184, and 1246Y to predominate in patients after treatment with amodiaquine 190 191 (11,13,24). Patients with mixed infections following treatment with DP were classified similarly

to those treated with ASAQ because piperaquine has been shown to exert selective pressure on *Pfmdr1* in the same direction as amodiaquine (25,26). We examined all recurrent infections,
which included recrudescent and new infections, rather than examining solely recrudescent
infections. New infections were included in this analysis because the *Pfmdr1* SNPs present posttreatment could make the parasite less susceptible to ACTs since the parasite was able to reinfect individuals soon after treatment, negating the potential post-treatment prophylactic effect
of the partner drug.

199 *Statistical analysis*

200 All statistical analyses were conducted using R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria). Multiple sensitivity analyses using only recrudescent infections 201 were done to assess potential bias that could occur when analyzing new infections and 202 203 recrudescent infections together. The first sensitivity analysis investigated the association between those treated with AL that experienced a recrudescent infection and *Pfmdr1* codons 86 204 205 and 184. This could not be done with *Pfmdr1* codon 1246 due to small sample size. A second 206 sensitivity analysis investigated the association between those treated with ASAQ who experienced a recrudescent infection and *Pfmdr1* codon 184. Due to the limited sample size, a 207 sensitivity analysis for those treated with ASAQ who experienced a recrudescent and *Pfmdr1* 208 209 codon 86 and 1246 could not be conducted. Similarly, a sensitivity analysis was not performed 210 for those treated with DP since so few recrudescent infections occurred in those receiving this ACT. After this, to determine whether patients infected with parasites carrying specific Pfmdr1 211 212 SNPs were at increased risk of recurrent (recrudescent or new) infections, the Mantel-Haenszel (MH) method was used to create forest plots. To ensure there was not significant heterogeneity 213 214 among studies, a Cochran's Q test was used (p > 0.05). Since no statistically significant

heterogeneity was found among studies, the common effect odds ratio was reported (27). Each
forest plot was created to display the common effect odds ratio by treatment arm for each
country-specific study and the pooled MH odds ratio by treatment arm when the data from all
studies were compiled.

The common effect odds ratio represented the odds of a specific SNP in recurrent 219 infections (in day of failure samples from those with recrudescent or new infections) compared 220 221 to the odds of that same SNP in successfully treated infections (in pre-treatment samples from 222 those who experienced an adequate clinical or parasitological response or in pre-treatment 223 samples who initially cleared their infection but would later acquire a new infection). For the 224 category of samples from successfully treated patients, we included: 1) pre-treatment samples from those with an adequate clinical and parasitological response; and 2) pre-treatment samples 225 226 from those who would go on to be infected with a different parasite (i.e., new infection). This is 227 because the pre-treatment infection was successfully cleared. For the category of unsuccessfully 228 treated patients, we included: 1) the post-treatment recrudescent samples; and 2) the post-229 treatment samples from those patients who were newly infected (because the patient experienced 230 an infection while the long-acting partner drug was still circulating). Conditional logistic regression was used to investigate the relationship between all the two-codon (e.g., 86Y and 231 Y184) and three-codon haplotype (e.g., N86, 184F, and D1246) combinations with the 232 occurrence of recurrent infections. 233

In patients who experienced either a recrudescent or new infection during the follow-up period, the *Pfmdr1* SNPs of the pre-treatment and recurrent sample were compared for each of these outcomes using McNemar's test to examine selection. SNPs from pre-treatment samples were compared to their corresponding recurrent infection SNP to confirm that differences

represented selection rather than original differences in SNP frequencies among the population

239 (9).

240 Results

241 Baseline prevalence of genetic markers associated with resistance

242 The baseline prevalence of SNPs was determined using all successfully sequenced pre-

treatment samples. Pre-treatment SNPs at position 86 were analyzed for 2,999 samples, at

position 184 for 3,050 samples, at position 1034 for 3,006 samples, at position 1042 for 3,006

samples, and at position 1246 for 3,027 samples (Table 1).

The prevalence of *Pfmdr1* SNPs varied by country (Table 1). The *Pfmdr1* N86 SNP was

found in the majority of samples from every country, with the prevalence ranging from 53–

248 100%. Samples from Ethiopia, Kenya, Mozambique, Tanzania, Uganda, and Zambia almost

exclusively carried the *Pfmdr1* N86 SNP. *Pfmdr1* 184 had the most variation, with the

250 prevalence of 184Y SNP ranging from 23–66%. Almost all samples carried parasites with the

251 *Pfmdr1* S1034 and *Pfmdr1* N1042 wild-type alleles except for two participants from the

252 Democratic Republic of the Congo, who carried parasites with both *Pfmdr1* 1034C and *Pfmdr1*

1042D. *Pfmdr1* D1246 SNP was found in 81–100% of the samples from most countries, with

the Democratic Republic of the Congo having *Pfmdr1* D1246 in 81% of samples.

255 Parasite single nucleotide polymorphisms as risk factors for recurrent infection

For patients treated with AL, the odds ratio between those with wild-type N86 in

recurrent infections and those with wild-type N86 in infections that were successfully cleared

was 5.22 (95% CI 2.69, 10.13) (Figure 2, panel a). For those treated with ASAQ, the odds of the

259 86Y SNP in recurrent infections was 2.72 (95% CI 1.28, 5.79) times higher than the odds of the

same SNP in infections that were successfully cleared (Figure 2, panel b). There was no

association detected between *Pfmdr1* codon 86 and recurrent infection for those treated with DP (Figure 2, panel c). Similarly, there was no association between *Pfmdr1* codons 184 or 1246 and recurrent infection in those treated with AL, ASAQ, or DP (Figures 3 and 4). When examining recrudescent infections alone (and not combined with new infections), the results of the sensitivity analysis were not statistically significant, although the odds ratios were either in the same direction as the aforementioned results or no effect was found (Supplementary Figures 1 and 2).

Country-specific odds ratios could not be generated for several countries for some treatment arms and SNPs. For example, patients who received AL in the Uganda TES only had parasites carrying the N86 SNP and none carrying the 86Y SNP following reclassification of mixed infections. Thus, the country-specific odds ratio was undefined and could not contribute to the overall, pooled MH odds ratio.

273 Post-treatment selection of genetic markers associated with reduced susceptibility

To examine changes in the genetic markers of parasites after drug treatment during the period of follow-up, we compared the prevalence of *Pfmdr1* SNPs in paired isolates from the initial and the recurrent parasites (Table 2). Statistically significant selection of *Pfmdr1* N86 occurred in new infections as well as recurrent infections (recrudescent infections plus new infections) after treatment with AL. There was no statistically significant selection of *Pfmdr1* SNPs at codons 184 or 1246 after AL treatment and no statistically significant selection of SNPs at *Pfmdr1* codons 86, 184, or 1246 after ASAQ or DP treatment.

281 Parasite haplotypes as a risk factor for recurrent infection

Recurrent infections, which included recrudescent and new infections, were pooled to assess the relationship between *Pfmdr1* haplotype and recurrent infections. Only one haplotype,

284	N86/184F, was found to be associated with recurrent infection. The odds of N86/184F among
285	individuals with recurrent infection after AL treatment (post-treatment) was 6.36 (95% CI 1.39,
286	29.19) times higher than the odds of the same haplotype among those that successfully cleared
287	the infection (pre-treatment). The combined effect of carrying N86/184F had a greater measure
288	of association (OR: 6.36, 95% CI: 1.39, 29.19) than recurrent parasites only carrying N86 (OR:
289	5.22, 95% CI: 2.69, 10.13). There was no statistically significant selection of <i>Pfmdr1</i> haplotypes
290	at codons 184 or 1246 after AL treatment and no statistically significant selection of haplotypes
291	at Pfmdr1 codons 86, 184, or 1246 after ASAQ or DP treatment.
292	
293	Discussion
294 295	This pooled analysis of data from 16 efficacy studies suggests that SNPs in <i>Pfmdr1</i> codon
296	86 influence recurrent infection after AL and ASAQ treatment. Individuals infected with
297	parasites that carried the <i>Pfmdr1</i> N86 SNP were statistically more likely to experience a
298	recurrent infection after treatment with AL. This finding is consistent with a previous study
299	which found that patients treated with AL and infected with parasites carrying the Pfmdr1 N86
300	allele were at statistically greater risk of treatment failure than those whose parasites carried
301	86Y(9). This increased risk of recurrent infection, in addition to significant selection of <i>Pfmdr1</i>
302	N86 by AL, could be an indicator of decreased susceptibility to the partner drug, lumefantrine.
303	For our haplotype analysis, patients given AL and infected with parasites carrying
304	<i>Pfmdr1</i> N86/184F were statistically more likely to cause a new infection. This finding is similar
305	to a study which found that after AL treatment, individuals carrying Pfmdr1 N86/184F/D1246
306	were able to re-infect with lumefantrine blood concentrations 15-fold higher than those with the
307	86Y/Y184/1246Y haplotype (8). Another study discovered that individuals with Pfmdr1

N86/D1246 experienced a new infection earlier after AL treatment (9). These findings suggest
that monitoring for decreasing post-treatment durations until a new infection has occurred or
surveilling for the prevalence of certain post-treatment *Pfmdr1* haplotypes may also provide
indications of decreased susceptibility to lumefantrine.

After treatment with ASAQ, individuals infected with parasites that carried the *Pfmdr1* 312 86Y SNP were statistically more likely to cause a recurrent infection, shown in this study. Like 313 our results from those treated with AL, a high prevalence of *Pfmdr1* 86Y SNP may be an early 314 315 warning signal of resistance to the partner drug, amodiaquine, but this association requires 316 further investigation because prior studies are collectively inconclusive. An *in vitro* analysis 317 from Southern Sudan found a significant association between failure after amodiaquine treatment and the combined presence of *Pfmdr1* 86Y and *Pfcrt* 76T but no association with *Pfmdr1* 86Y 318 319 alone (28). However, an *in vivo* study from Burkina Faso found a significant association between *Pfmdr1* 86Y and treatment failures after amodiaguine treatment and another *in vivo* study from 320 321 Burkina Faso showed significant selection of *Pfmdr1* 86Y after treatment with ASAQ (24,29). 322 Additionally, a meta-analysis revealed that the risk of therapeutic failure was greater for participants who carried *Pfmdr1* 86Y and were treated with amodiaquine monotherapy (30). Our 323 results align with the findings from Burkina Faso and the meta-analysis. Close monitoring of the 324 325 prevalence of *Pfmdr1* codon 86 before and after treatment with amodiaguine monotherapy or ASAQ could be used to indicate potential partner-drug resistance to amodiaquine. 326 Unlike previous studies, this analysis did not find statistically significant selection of 327 328 *Pfmdr1* SNPs by ASAQ (9,11,31–34). There were no significant findings between the use of DP and treatment outcomes or selection of *Pfmdr1* SNPs by DP. While this lack of association has 329 330 been found before, there has also been evidence of piperaquine exerting a selective pressure on

331 *Pfmdr1* genes similar to amodiaquine (25,26). However, there was clear evidence of significant 332 selection of *Pfmdr1* N86 by AL in those who experienced either a recurrent infection (i.e., 333 recrudescent or new infection) or a new infection alone in this study. This result aligns with prior 334 studies that found selection of particular *Pfmdr1* SNPs among parasite populations after treatment with AL (8,9,12,15,17,35–40). Additionally, the significant selection of *Pfmdr1* N86 335 by AL is consistent with prior molecular studies that identified changes in the parasite population 336 prevalence of *Pfmdr1* SNPs after the introduction or greater use of lumefantrine (14,15,34– 337 37,41,42). 338

339 Although SNPs at *Pfmdr1* codon 86 were associated with recurrent infections (i.e., recrudescent or new infections), they were not associated solely with recrudescent infections in 340 those treated with AL or ASAQ, an association shown in a prior study (9). The small number of 341 342 recrudescent infections, a limitation of this study even with pooled data across 16 TES, may have prevented this analysis from finding significant results. A similar limitation was the smaller 343 344 number of patients receiving ASAQ, which may have contributed to the lack of evidence of 345 selection for *Pfmdr1* 86Y by ASAQ, a selection other studies have demonstrated [16, 23, 49–51]. Another limitation was that information on the number of *Pfmdr1* copies was not available for 346 the majority of studies included in this analysis but has been previously found as a predictor of 347 348 treatment failure after AL treatment (10,17). Additionally, most of the efficacy studies enrolled patients under 6 years old. Therefore, our data may not be applicable to adult populations. Lastly, 349 efficacy studies are not countrywide but occur in just a few sites, which may not be 350 representative of an entire country's parasite population. Despite its limitations, our study 351 possessed many strengths, including the large number of samples from numerous countries that 352 353 were sequenced at the same laboratory using the same methodology.

Two patients from the Democratic Republic of the Congo carried parasites bearing the *Pfindr1* haplotype commonly found in South America, *Pfindr1* 1034C, 1042D, and 1246Y, which has been associated with increased sensitivity to artemisinin (39,43,44). However, in our study, the participants experienced a new infection after treatment with DP. Because detailed travel histories were not available for these patients, it is unknown whether they acquired their infections locally or abroad.

360 Changes in the prevalence of *Pfmdr1* SNPs over multiple TESs can be a subtle sign of selection of parasite populations by AL or ASAQ. Decreasing efficacy of lumefantrine, 361 362 amodiaquine, or other partner drugs leaves the artemisinin component of an ACT vulnerable to 363 new selective pressures. Modeling demonstrates that partner drug resistant *Pfmdr1* genotypes may lead to establishment of artemisinin resistance (45). This phenomenon may already be 364 365 occurring in Africa. Rwanda and Uganda, two countries reporting K13 mutations associated with artemisinin resistance, use AL as their first-line ACT and had a predominance of the Pfmdr1 N86 366 367 genotype in our study (7,46,47). Previous studies have shown that ASAQ and AL exert opposing 368 selecting pressures on *Pfmdr1* 86 (9). Depending on the prevalence of *Pfmdr1* polymorphisms, the opposing selection by the partner drugs could better inform which ACT national malaria 369 control programs could choose as a first-line therapy to delay resistance to both drugs. New 370 371 strategies, such as multiple first-line therapies or dosing lumefantrine and amodiaquine together 372 as part of a triple therapy, may overcome the negative effects of a particular *Pfmdr1* SNPs 373 associated with decreased susceptibility to partner drugs, although that remains to be proven (48– 374 50). Monitoring prevalence of *Pfmdr1* codons, such as N86Y, may indicate a parasite genetic 375 background conferring reduced susceptibility to a particular antimalarial.

376

377 Acknowledgements

- The authors would like to acknowledge Venkatachalam Udhayakumar for his suggestions on the
- 379 manuscript and for supporting the laboratory genotyping trainings vital to this multi-country
- endeavor. All authors have no conflicts of interest.
- 381

382 Funding

- Funding for this assessment was obtained from the United States President's Malaria Initiative
- (PMI) via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, US
- Agency for International Development. Staff from PMI were involved in the development of the
- protocol, survey tools, survey implementation, data analysis, and manuscript preparation.

387 Disclaimer

- 388 The opinions expressed herein are those of the author(s) and do not necessarily reflect the views
- of any collaborating institute including the Centers for Disease Control and Prevention or the US
- 390 Agency for International Development.

391 **References**

392 WHO Guidelines for malaria [Internet]. [cited 2023 Jun 12]. Available from: 1. 393 https://www.who.int/publications-detail-redirect/guidelines-for-malaria 394 2. World malaria report 2021 [Internet]. [cited 2023 Jun 12]. Available from: 395 https://www.who.int/publications-detail-redirect/9789240040496 396 3. Shibeshi W, Alemkere G, Mulu A, Engidawork E. Efficacy and safety of artemisinin-based 397 combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic 398 review and meta-analysis. BMC Infect Dis. 2021 Apr 7;21(1):326. 399 4. Pluijm RW van der, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of 400 dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, 401 Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect 402 Dis. 2019 Sep 1;19(9):952-61. 403 5. Gansané A, Moriarty LF, Ménard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy 404 and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows 405 inadequate efficacy in children in Burkina Faso, 2017–2018. Malar J. 2021 Jan 19;20(1):48. 406 6. Moriarty LF, Nkoli PM, Likwela JL, Mulopo PM, Sompwe EM, Rika JM, et al. Therapeutic Efficacy of 407 Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation 408 of Molecular Markers of Antimalarial Resistance. Am J Trop Med Hyg. 2021 Sep 7;tpmd210214. 409 7. Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety 410 of artemether-lumefantrine and dihydroartemisinin-piperaguine for the treatment of 411 uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated 412 with artemisinin and partner drug resistance in Uganda. Malar J. 2021 Dec 24;20(1):484. 413 8. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, et al. Plasmodium falciparum 414 Drug Resistance Phenotype as Assessed by Patient Antimalarial Drug Levels and Its Association 415 With pfmdr1 Polymorphisms. J Infect Dis. 2013 Mar 1;207(5):842-7. 416 9. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. 417 Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug 418 Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P. falciparum 419 Malaria after Artemether-Lumefantrine and Artesunate-Amodiaguine. Am J Trop Med Hyg. 2014 420 Oct 1;91(4):833-43. 421 Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, et al. Pfmdr1 copy number and 10. 422 arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J. 423 2009 Jan 12;8(1):11. 424 11. Otienoburu SD, Maïga-Ascofaré O, Schramm B, Jullien V, Jones JJ, Zolia YM, et al. Selection of 425 Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunateamodiaquine fixed dose combination or artemether-lumefantrine in Liberia. Malar J. 2016 Sep 426 427 5;15(1):452.

Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A, et al. The role of
 pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int
 Health. 2007 Jun 1;12(6):736–42.

- Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, et al. Association between
 mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum
 multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected
 children in Nigeria. Am J Trop Med Hyg. 2006 Jul;75(1):155–61.
- Baliraine FN, Rosenthal PJ. Prolonged Selection of pfmdr1 Polymorphisms After Treatment of
 Falciparum Malaria With Artemether-Lumefantrine in Uganda. J Infect Dis. 2011 Oct
 1;204(7):1120-4.
- Maiga H, Grivoyannis A, Sagara I, Traore K, Traore OB, Tolo Y, et al. Selection of pfcrt K76 and
 pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in
 Mali. Int J Mol Sci. 2021 Jan;22(11):6057.
- 44116.White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malar J. 2008 Jan44211;7(1):9.
- Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, et al. Molecular and
 Pharmacological Determinants of the Therapeutic Response to Artemether-Lumefantrine in
 Multidrug-Resistant Plasmodium falciparum Malaria. Clin Infect Dis. 2006 Jun 1;42(11):1570–7.
- Halsey ES, Venkatesan M, Plucinski MM, Talundzic E, Lucchi NW, Zhou Z, et al. Capacity
 Development through the US President's Malaria Initiative–Supported Antimalarial Resistance
 Monitoring in Africa Network. Emerg Infect Dis. 2017 Dec;23(Suppl 1):S53–6.
- 449 19. World Health Organization. Methods for surveillance of antimalarial drug efficacy [Internet]. World
 450 Health Organization; 2009 [cited 2022 Mar 22]. Available from:
 451 https://apps.who.int/iris/handle/10665/44048
- Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V. Robust Algorithm for Systematic
 Classification of Malaria Late Treatment Failures as Recrudescence or Reinfection Using
 Microsatellite Genotyping. Antimicrob Agents Chemother. 2015 Sep 18;59(10):6096–100.
- Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, Rosenthal PJ, et al. Validation of
 microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J
 Trop Med Hyg. 2006 Nov;75(5):836–42.
- 458 22. Medicines for Malaria Venture, Organization WH. Methods and techniques for clinical trials on antimalarial drug efficacy¹: genotyping to identify parasite populations¹: informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health
 461 Organization, 29-31 May 2007, Amsterdam, The Netherlands [Internet]. World Health
- 462 Organization; 2008 [cited 2022 Nov 30]. Available from:
- 463 https://apps.who.int/iris/handle/10665/43824

Chebore W, Zhou Z, Westercamp N, Otieno K, Shi YP, Sergent SB, et al. Assessment of molecular
markers of anti-malarial drug resistance among children participating in a therapeutic efficacy
study in western Kenya. Malar J. 2020 Aug 14;19(1):291.

- Sondo P, Derra K, Nakanabo SD, Tarnagda Z, Kazienga A, Zampa O, et al. Artesunate-Amodiaquine
 and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro,
 Burkina Faso. PLOS ONE. 2016 Mar 31;11(3):e0151565.
- 25. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Comparative impacts over
 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms
 that modulate drug sensitivity in Ugandan children. J Infect Dis. 2014 Aug 1;210(3):344–53.
- 473 26. Taylor SM, Juliano JJ. Artemisinin Combination Therapies and Malaria Parasite Drug Resistance:
 474 The Game Is Afoot. J Infect Dis. 2014 Aug 1;210(3):335–7.
- 27. Dettori JR, Norvell DC, Chapman JR. Fixed-Effect vs Random-Effects Models for Meta-Analysis: 3
 Points to Consider. Glob Spine J. 2022 Sep;12(7):1624.
- 477 28. Ochong EO, van den Broek IVF, Keus K, Nzila A. Short report: association between chloroquine and 478 amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 479 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern 480 Sudan. Am J Trop Med Hyg. 2003 Aug;69(2):184–7.
- 481 29. Tinto H, Guekoun L, Zongo I, Guiguemdé RT, D'Alessandro U, Ouédraogo JB. Chloroquine482 resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina
 483 Faso. Trop Med Int Health TM IH. 2008 Feb;13(2):238–40.
- Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and
 meta-analysis of evidence for correlation between molecular markers of parasite resistance and
 treatment outcome in falciparum malaria. Malar J. 2009 May 4;8(1):89.
- 487 31. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Björkman A. Amodiaquine resistant
 488 Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y.
 489 Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2006 Jul;6(4):309–14.
- 490 32. Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, Safety, and Selection of
 491 Molecular Markers of Drug Resistance by Two ACTs in Mali. Am J Trop Med Hyg. 2008 Mar
 492 1;78(3):455–61.
- 33. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, et al. Evidence for selection
 for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and
 amodiaquine. Parasitology. 1997 Mar;114 (Pt 3):205–11.
- 496 34. Lekana-Douki JB, Dinzouna Boutamba SD, Zatra R, Zang Edou SE, Ekomy H, Bisvigou U, et al.
 497 Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates
 498 from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and
 499 artesunate-mefloquine. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2011
 500 Mar;11(2):512–7.

501 Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJM, Mutabingwa TK, Sutherland CJ, et al. 35. 502 Amodiaguine and Artemether-Lumefantrine Select Distinct Alleles of the Plasmodium falciparum 503 mdr1 Gene in Tanzanian Children Treated for Uncomplicated Malaria. Antimicrob Agents 504 Chemother [Internet]. 2007 Mar; Available from: 505 https://journals.asm.org/doi/abs/10.1128/AAC.00875-06 506 36. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, et al. In vivo selection 507 of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J 508 Infect Dis. 2005 Mar 15;191(6):1014–7. 509 Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of Plasmodium 37. 510 falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda 511 where malaria is highly endemic. Antimicrob Agents Chemother. 2006 May;50(5):1893–5. 512 38. Somé AF, Séré YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, et al. Selection of Known 513 Plasmodium falciparum Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and 514 Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperaquine in Burkina 515 Faso. Antimicrob Agents Chemother. 2010 May;54(5):1949-54. 39. 516 Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, et al. Increased pfmdr1 copy number 517 and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients 518 treated with artemether-lumefantrine. Antimicrob Agents Chemother. 2011 Nov;55(11):5408–11. 519 40. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, et al. Selection of 520 Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by 521 artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob 522 Agents Chemother. 2009 Mar;53(3):888-95. 523 Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK, et al. In vivo selection of 41. 524 Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and 525 dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2015 526 Jan;59(1):734-7. 527 Zhou Z, Gimnig JE, Sergent SB, Liu Y, Abong'o B, Otieno K, et al. Temporal trends in molecular 42. 528 markers of drug resistance in Plasmodium falciparum in human blood and profiles of 529 corresponding resistant markers in mosquito oocysts in Asembo, western Kenya. Malar J. 2022 Sep 530 13;21(1):265. 531 Sidhu ABS, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and 43. 532 enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol. 533 2005;57(4):913-26. 534 Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, et al. Globally prevalent 44. 535 PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based 536 combination therapies. Nat Commun. 2016 May 18;7(1):11553. 537 45. Watson OJ, Gao B, Nguyen TD, Tran TNA, Penny MA, Smith DL, et al. Pre-existing partner-drug 538 resistance to artemisinin combination therapies facilitates the emergence and spread of 539 artemisinin resistance: a consensus modelling study. Lancet Microbe. 2022 Sep 1;3(9):e701-10.

46. Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of
Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an
open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021 Aug
1;21(8):1120–8.

- 54447.Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of545Artemisinin-Resistant Malaria in Africa. N Engl J Med. 2021 Sep 23;385(13):1163–71.
- 54648.Boni MF, White NJ, Baird JK. The Community As the Patient in Malaria-Endemic Areas: Preempting547Drug Resistance with Multiple First-Line Therapies. PLOS Med. 2016 Mar 29;13(3):e1001984.
- 49. Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HDT, Nguon C, et al. Triple therapy with artemetherlumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant,
 uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect Dis.
 2022 Jun;22(6):867–78.
- 55250.Boni MF. Breaking the cycle of malaria treatment failure. Front Epidemiol [Internet]. 2022;2.553Available from: https://www.frontiersin.org/articles/10.3389/fepid.2022.1041896

565 Tables & Figures



Legend

- Countries with therapeutic efficacy sites
- Therapeutic efficacy site

566

Figure 1. Countries and sites contributing data to this *Pfmdr1* meta-analysis

Country	Sites	ACT(s) studied*	Study year(s)	Patient age	Number of samples	Number of patients who completed study	Genotyping method	Publication
	Uige, Zaire	AL, DP	2013	6 mo–9 y	50	320	Microsatellites	(1)
Angolo	Benguela, Lunda Sul, Zaire	AL, ASAQ, DP	2015	6 mo-12 y	467	467	Microsatellites	(2,3)
Aligola	Benguela, Lunda Sul, Zaire	AL, ASAQ, DP	2017	6 mo–12 y	76	540	Microsatellites	(4)
	Benguela, Lunda Sul, Zaire	AL, ASAQ	2019	6 mo–12 y	106	579	Microsatellites	(5)
Benin	Klouékanmey, Djougou	AL	2017	6 mo–59 mo	175	235	Microsatellites	Country report
DRC	Kabondo, Kapolowe, Kimpese, Mikalayi, Rutshuru	AL, ASAQ, DP	2017-2018	6 mo–59 mo	520	1,271	Microsatellites	(6)
Ethiopia	Arba Minch, Pawe	AL, DP	2017	>6 mo	50	170	Microsatellites	(7)
Guinea	Labé, Maferinyah	AL, ASAQ	2016	6 mo–59 mo	443	413	Microsatellites	(8)
Kenya	Siaya	AL, DP	2016-2017	6 mo–59 mo	415	270	msp1, msp2, glurp	(9, 10)
Madagascar	Ankazomborona, Antensenavolo, Kianjavato, Matanga, Vohitromby	AL, ASAQ	2018	6 mo–14 y	179	335	Microsatellites	(11)
Mali	Sélingué	AL, ASAQ	2015-2016	6 mo–59 mo	386	434	msp1, msp2, glurp	(12)
Mozambique	Massinga, Moatize, Montepuez Mopeia	AL, ASAQ	2018	6 mo–59 mo	158	641	Microsatellites	(13, 14)
Rwanda	Bugarama, Masaka, Rukara	AL	2018	6 mo–59 mo	243	224	Microsatellites	(15)
Tanzania	Kibaha, Mkuzi, Mlimba, Ujiji	AL	2016	6 mo–10 y	339	335	Microsatellites	(16)
Uganda	Aduku, Arua, Masafu	AL, DP	2018-2019	6 mo–10 y	256	590	Microsatellites	(17)
Zambia	Gwembe, Katete, Mansa	AL, ASAQ, DP	2016	>6 mo	266	291	Microsatellites	Country report

Supplementary Table 2. Summary of antimalarial therapeutic efficacy studies, thirteen countries in Africa, 2013–2019

*ACTs, artemisinin-based combination therapies; AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; *msp1, merozoite surface protein-1*; *msp2, merozoite surface protein-2*; *glurp, glutamate-rich protein*; DRC, Democratic Republic of the Congo

Marker	Angola	Benin	DRC	Ethiopia	Guinea	Kenya	Madagascar	Mali	Mozambique	Rwanda	Tanzania	Uganda	Zambia	Total
Number of samples	572	164	260	48	420	320	157	311	109	208	271	128	230	3.135
<i>Pfmdr1</i> [†] 86				-				-				-		
Sequenced	511	152	258	48	385	320	153	255	109	208	269	128	203	2,999
Ν	433 (85)	144 (89)	138 (53)	47 (99)	306 (80)	319 (99)	120 (78)	206 (81)	109 (100)	200 (95)	268 (99)	128 (100)	202 (99)	2,620 (87)
N/Y	8 (2)	1 (<1)	38 (15)	0	24 (6)	1 (<1)	4 (3)	15 (6)	0	5 (4)	0	0	0	96 (3)
Y	70 (13)	17 (10)	82 (32)	1 (<1)	55 (14)	0	29 (19)	34 (13)	0	3 (<1)	1 (<1)	0	1 (<1)	293 (10)
<i>Pfmdr1</i> 184														`
Sequenced	512	162	258	48	385	320	154	293	109	208	270	128	203	3,050
Y	341 (66)	43 (27)	150 (58)	11 (23)	119 (31)	130 (41)	53 (34)	83 (28)	42 (39)	99 (47)	165 (61)	48 (37)	127 (63)	1,411 ≧ (46) ਛੁੱ
Y/F	39 (8)	27 (17)	60 (23)	2 (4)	56 (14)	77 (24)	9 (6)	34 (12)	24 (22)	20 (10)	0	37 (29)	4 (2)	389 hts (14) r
F	132 (26)	92 (56)	48 (19)	35 (73)	210 (55)	113 (35)	92 (60)	176 (60)	43 (39)	89 (43)	105 (39)	43 (34)	72 (35)	1,250 Se (40) Z
<i>Pfmdr1</i> 1034								<u> </u>						ed. r
Sequenced	503	150	260	47	374	320	149	307	109	207	270	126	184	3,006
S	503 (100)	150 (100)	258 (99)	47 (100)	374 (100)	320 (100)	149 (100)	307 (100)	109 (100)	207 (100)	270 (100)	126 (100)	184 (100)	3,004 USe (99) 8
S/C	0	0	0	0	0	0	0	0	0	0	0	0	0	
С	0	0	2 (<1)	0	0	0	0	0	0	0	0	0	0	2 (<1)
Pfmdr1 1042														
Sequenced	503	150	260	48	374	320	149	307	109	206	270	127	183	3,006 H
Ν	503 (100)	150 (100)	258 (99)	48 (100)	374 (100)	320 (100)	149 (100)	307 (100)	109 (100)	206 (100)	270 (100)	127 (100)	183 (100)	3,004 permi (99) mis
N/D	0	0	0	0	0	0	0	0	0	0	0	0	0	0 0
D	0	0	2 (<1)	0	0	0	0	0	0	0	0	0	0	2 (<1)
<i>Pfmdr1</i> 1246														
Sequenced	513	150	260	48	371	320	139	307	109	208	270	127	205	3,027
D	505 (98)	150 (100)	210 (81)	48 (100)	362 (97)	289 (89)	133 (96)	302 (98)	10 (100)	194 (93)	268 (99)	116 (91)	201 (98)	2,887 (95)
D/Y	0	0	18 (7)	0	3 (1)	(20 (7)	0	0	0	4 (2)	0	5 (4)	2 (1)	52 (2)
Y	8 (2)	0	32 (12)	0	6 (2)	11 (4)	6 (4)	5 (2)	0	10 (5)	2(1)	6 (5)	2(1)	88 (3)

 Table 1. Baseline (pre-treatment) prevalence of Pfmdr1 single nucleotide polymorphisms*

*Values are no. (%) of successfully sequenced samples [†]*Pfmdr1=Plasmodium falciparum multidrug resistance 1* gene.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.01.24309724; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Maalaan	C	Recu	urrent infec	tion	Recrud	lescent infe	ction	New infec			ion	
Marker	Genotype	AL	ASAQ	DP		ASAQ	DP		AL	ASAQ	DP	
Pfmdr1 86	N→Y	(11/647)	(9/99)	(22/205)	(1/153)	(1/27)	(2/37)		(10/494)	(8/72)	(20/168)	
	Y→N	(32/647)	(22/99)	(26/205)	(3/153)	(5/27)	(3/37)		(29/494)	(17/72)	(23/168)	
	No change**	(604/647)	(68/99)	(157/205)	□ (149/153)	(21/27)	(32/37)		(455/494)	(47/72)	(125/168)	
P value		<0.01	0.03 (exact)	0.56	□ 0.62	0.22 (exact)	1 (exact)		<0.01	0.11 (exact)	0.65	
Pfmdr1 184	Y→F	(119/639)	(17/101)	(44/205)	(22/153)	(15/36)	(7/37)		(95/486)	(10/74)	(39/168)	
	$F \rightarrow Y$	(117/639)	(16/101)	(35/205)	(27/153)	(2/36)	(5/37)		(92/486)	(15/74)	(28/168)	
	No change**	(403/639)	(68/101)	(126/205)	□ (104/153)	(19/36)	(25/37)		(299/486)	(49/74)	(101/168)	
P value		0.89	1	0.31	□ 0.48	0.29 (exact)	0.77 (exact)		0.82	0.42 (exact)	0.18	
Pfmdr1 1246	D→Y	(9/618)	(6/105)	(16/205)	(2/150)	(2/27)	(2/37)		(7/468)	(6/78)	(14/168)	
	Y→D	(17/618)	(8/105)	(9/205)	(2/150)	(2/27)	(2/37)		(15/468)	(4/78)	(7/168)	
	No change**	(592/618)	(91/105)	(180/205)	□ (146/150)	(23/27)	(33/37)		(446/468)	(68/78)	(147/168)	
P value		0.17	0.77 (exact)	0.16	\square 1	1 (exact)	1 (exact)		0.14	0.75 (exact)	0.19	

Table 2. Selection of *Pfmdr1* genotypes after treatment with artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine*

AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine

*Values in bold indicate statistically significant selection (P<0.05) using McNemar's paired test. Those marked exact were tested by using the exact distribution for sample sizes less than 100.

Pfmdr1=Plasmodium falciparum multidrug resistance 1 gene

 \pm Each category includes all changes from one allele to another. For example, N \rightarrow Y includes N \rightarrow Y, N \rightarrow N/Y, and N/Y \rightarrow Y changes; Y \rightarrow N includes Y \rightarrow N, Y \rightarrow N/Y, N/Y \rightarrow N changes.

**No change in genotype from before and after treatment.

Note: recurrent infections are the combination of recrudescent and new infections







	1.05 [0.36; 3.11]
*	0.27 [0.01; 8.46] 1.71 [1.00; 2.92] 0.35 [0.01; 20.14] 0.49 [0.09; 2.63]
	1.37 [0.87; 2.14]
	1 0.1 1 10

medRxiv (which

was not

t doi:

rtified b



Studies using ASAQ, codon 1246 (n=518; 78 recurrences)	Odds Ratio	OR 9
Angola, 2015 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Zambia, 2016		- 33.92 [1.25; 9 0.75 [0.04; 0.87 [0.36; 1.86 [0.10; 3 2.59 [0.11; 0 - 14.56 [0.40; 5
Common effect model		0.96 [0.43;

)				
·	Studies using DP, codon 1246 (n=547; 167 recurrences)	Odds Ratio	OR	95%-C
	Angola, 2015		0.29 1.58	[0.01; 7.46 [0.72: 3.46
	Common effect model		1.60	0 [0.73; 3.4

<page-header><page-header><page-header><page-header><page-header><page-header><page-header>

Supplementary	Table 1.	Uncorrected a	and PCR-corre	cted efficacies	s for therap	eutic efficacy	v study sites
----------------------	----------	---------------	---------------	-----------------	--------------	----------------	---------------

Country	Site	Year(s) of study	AL uncorrected efficacy (%, 95% CI)	AL PCR- corrected efficacy (%, 95% CI)	ASAQ uncorrected efficacy (%, 95% CI)	ASAQ PCR- corrected efficacy (%, 95% CI)	DP uncorrected efficacy (%, 95% CI)	DP PCR- corrected efficacy (%, 95% CI)
	Uige	2012	92 [84–97]	97 [91–100]			100 ^a	
	Zaire	2013	77 [69–87]	88 [79–95]*	_	_	99 [96–100]	100^{a}
	Benguela	_	90 [83–96]	96 [89–99]	90 [84–97]	99 [95–100]		
	Lunda Sul	2015	_	_	100	100	100	100
	Zaire		76 [68–85]	88 [81–95]*			96 [91–100]	99 [96–100]
Angola	la Benguela Lunda Sul		_	_	99 [97–100]	100 [97–100]	100 [100– 100]	100
		2017	90 [82–95]	96 [90–99]	_	_	101 [100– 100]	101 [100– 100]
	Zaire		93 [88–98]	96 [91–100]	82 [75–90]	93 [88–99]		
	Benguela		90 [85–96]	98 [96–100]	100 ^a	100 ^a	_	_
	Lunda Sul	2019	85 [79–93]	88 [81–95]*	100^{a}	100 ^a	_	_
	Zaire		84 [77–92]	92 [87–98]	85 [78–92]	96 [91–100]	_	_
Ponin	Klouékanmey		99 [94–100]	100 [97–100]	_	_	_	_
Denni	Djougou	2017	91 [83–98]	98 [94–100]			—	_
	Kabondo		88 [82–95]	98 [95–100]	100 [100–100]	100 [100–100]	91 [85–98]	100 [99–100]
	Kapolowe	2017	76 [68–85]	94 [89–99]	100 [100–100]	100 [100–100]	64 [56–75]	93 [87–99]
DRC	Kimpese	2017-	85 [78–94]	96 [92–100]	93 [88, 99]	99 [98–100]	90 [84–97]	100 [99-100]
	Mikalayi	2010	63 [55–74]	86 [79, 93]*	77 [69–86]	96 [91–99]	56 [47–67]	84 [75–93]*
	Rutshuru		80 [72-89]	96 [92–100]	73 [64–83]	91 [85–98]	59 [50-70]	95 [90–100]
Ethiopia	Arbaminch	2017	100^{a}	100^{a}	_	_	100^{a}	100^{a}
Linopia	Pawe	2017	98 [91–99]	98 [91–99]	_	_	100^{a}	100^{a}
Cuinco	Labé	2016	94 [90–99]	99 [97–100]	97 [94–100]	99 [97–100]	_	_
Guillea	Maferinyah	2010	92 [87–98]	100^{a}	95 [91–99]	100 ^a		
Kenya	Siaya	2016– 2017	68 [61–76]	91 [86–96]	_	_	77 [70–84]	94 [89–98]

Madagagag	Ankazomborona	2010	99 [97–100]	100 [99–100]	100 [100-100]	100 [100-100]	_	_
Madagascar	Matanga	2018	83 [76–92]	95 [91–100]	95 [91–100]	98 [95–100]	_	_
	Sélingué	2015-						
Mali	Senngue	2016	84 [79–89]	92 [88–97]	93 [90–97]	97 [95–99]	_	_
Mozambique	Massinga	2018	73 [62–82]	95 [87–99]	99 [94–100]	100 [96–100]	_	_
	Moatize		98 [91–100]	100 [95–100]	_	_	_	_
	Montepuez		96 [90–99]	100 [96–100]	100 [96–100]	100 [96–100]	_	_
	Mopeia		76 [66–85]	96 [88–99]	98 [92–100]	99 [94–100]	_	_
Rwanda	Bugarama	2018	84 [75–91]	97 [91–100]	_	_	_	_
	Masaka		96 [86–100]	97 [88–100]	_	_	_	_
	Rukara		76 [65–84]	94 [85–98]	_	_	_	_
Tanzania	Kibaha	2018	86 [76–92]	99 [93–100]	_	_	_	_
	Mkuzi		65 [54–75]	97 [88–100]	_	_	_	_
Tanzania	Mlimba	2010	86 [77–93]	100 [94–100]	_	_	_	_
	Ujiji		74 [63–83]	99 [92–100]	_	_	_	_
	Kwania	2018-	71 [61–80]	94 [90–99]	_	_	87 [81–94]	98 [95–100]
Uganda	Arua		61 [50–70]	92 [86–98]	_	_	79 [71–88]	94 [90–99]
	Busia	2019	41 [32–51]	87 [67–90]*	_	_	74 [65–83]	92 [87–98]
$Zambia^{\dagger}$	Gwembe							
	Katete 2016	2016	86 [77–93]	100 [95–100]	98 [92–100]	100 [96–100]	87 [78–93]	100 [95–100]
	Mansa							

*PCR-corrected efficacy less than WHO suggested 90% threshold

Hyphens indicate a drug was not used in the study

a=Confidence intervals are undefined

[†]Uncorrected and PCR-corrected efficacies were calculated from Gwembe, Katete, and Mansa samples pooled together AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; CI, confidence interval.



Supplementary Figure 1. Forest plot of recrudescent infection in patients treated with AL. Odds ratio of N86 among patients with recrudescent infection compared to the odds ratio of N86 among patients who successfully cleared the infection. OR, odds ratio; CI, confidence interval.

	Studies using AL, codon 184 (n=1,222; 105 recrudescences)	Odds Ratio	OR	95%-CI	
	Angola, 2013		- 0.82 [0.0	1: 50.021	
	Angola, 2015		1.87 [0.	48: 7.30]	
	Angola, 2017		- 0.78 [0.0	1; 49.90]	
	Angola, 2019		0.47 [0.0	1; 28.73]	
	Benin, 2017		1.09 [0.1	1; 10.83]	
	Democratic Republic of the Congo, 2018		0.52 [0.0	1; 28.30]	
	Ethiopia, 2018	·	0.32 [0.0	1; 17.63]	
	Guinea, 2016		- 1.82 [0.0	07; 45.38]	
	Madagascar, 2018	<u>T:</u>	1.02 [0.1	0; 10.59]	
	Mali, 2016	ī	0.99 [0.0	9; 11.25]	
	Mozambique, 2018			5; 141.54]	
	Tenzenia 2016		0.56 [0. 	7. 107 991	
	Uganda, 2019		- 1.24 [0.0	2: 69.011	
	Zambia, 2016		0.67 [0.0	3: 17.30]	
			cier [eit		
	Common effect model	-	1.42 [0.0	59; 2.93]	
		0.01 0.1 1 10	100		
		0.01 0.1 1 10	100		
• `					
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences) Odds Ratio	OR	95%-CI	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015	;) Odds Ratio	OR	95%-CI 0.14: 2.091	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017	c) Odds Ratio	OR 0.54 [(1.29 [0	95%-Cl 0.14; 2.09] .02; 82.49]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019	s) Odds Ratio	OR 0.54 [0 1.29 [0 2.14 [0.	95%-Cl 0.14; 2.09] .02; 82.49] 03; 131.93]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018	5) Odds Ratio	OR 0.54 [(1.29 [0 2.14 [0. 1.94 [0.	95%-Cl 0.14; 2.09] 02; 82.49] 03; 131.93] 04; 106.66]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016	5) Odds Ratio	OR 0.54 [(1.29 [0 2.14 [0. 1.94 [0. 0.55 [0	95%-Cl 0.14; 2.09] 0.02; 82.49] 03; 131.93] 04; 106.66] .02; 13.67]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018	e) Odds Ratio	OR 0.54 [(1.29 [0 2.14 [0. 1.94 [0. 0.55 [0 0.98 [0]	95%-Cl 0.14; 2.09] 02; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 09; 10.13]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Mozambique, 2019	e) Odds Ratio	OR 0.54 [0 1.29 [0 2.14 [0. 0.55 [0 0.98 [0 0.14 [0]	95%-Cl 0.14; 2.09] 02; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 09; 10.13] 0.01; 2.66]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Mozambique, 2019 Zambia, 2016	Odds Ratio	OR 0.54 [0 1.29 [0 2.14 [0. 0.55 [0 0.98 [0 0.14 [0 1.48 [0]	95%-Cl 0.14; 2.09] 02; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 09; 10.13] 0.01; 2.66] 0.06; 37.99]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Mozambique, 2019 Zambia, 2016 Common effect model	e) Odds Ratio	OR 0.54 [0 1.29 [0 2.14 [0. 1.94 [0. 0.55 [0 0.98 [0 0.14 [0 1.48 [0 0.44 [0]	95%-Cl 0.14; 2.09] 02; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 0.01; 2.66] 0.01; 2.66] 0.06; 37.99]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Mozambique, 2019 Zambia, 2016 Common effect model	b) Odds Ratio	OR 0.54 [(1.29 [0 2.14 [0. 0.55 [0 0.98 [0 0.14 [(1.48 [0 0.44 [(100	95%-Cl 0.14; 2.09] 02; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 09; 10.13] 0.01; 2.66] 0.06; 37.99]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Mozambique, 2019 Zambia, 2016 Common effect model	 Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio 	OR 0.54 [(1.29 [0 2.14 [0. 1.94 [0. 0.55 [0 0.98 [0 0.14 [0 1.48 [0 0.44 [0 100	95%-Cl 0.14; 2.09] 0.2; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 09; 10.13] 0.01; 2.66] 06; 37.99]	
b)	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Mozambique, 2019 Zambia, 2016 Common effect model	Odds Ratio	OR 0.54 [(1.29 [0 2.14 [0. 0.55 [0 0.98 [0 0.14 [(1.48 [0 0.44 [(100	95%-Cl 0.14; 2.09] 02; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 09; 10.13] 0.01; 2.66] 0.06; 37.99]	
b) mentary Figur	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Mozambique, 2019 Zambia, 2016 Common effect model	b) Odds Ratio -	OR 0.54 [(1.29 [0 2.14 [0. 1.94 [0. 0.55 [0 0.98 [0 0.14 [(1.48 [0] 0.44 [0 100 100	95%-Cl 0.14; 2.09] 0.02; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 0.09; 10.13] 0.01; 2.66] 0.06; 37.99] 0.16; 1.26]	crudescent in
b) mentary Figured to the odds	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Mozambique, 2019 Zambia, 2016 Common effect model	b) Odds Ratio Odds Ratio	OR 0.54 [(1.29 [0 2.14 [0. 1.94 [0. 0.55 [0 0.98 [0 0.14 [0 1.48 [0 0.44 [0 100 100 184F amon recrudescen	95%-Cl 0.14; 2.09] 02; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 0.09; 10.13] 0.01; 2.66] 0.06; 37.99] 0.16; 1.26] g patients with reconstruction in patients	crudescent in ents treated w
b) mentary Figur ed to the odds	Studies using ASAQ, codon 184 (n=528; 62 recrudescences Angola, 2015 Angola, 2017 Angola, 2019 Democratic Republic of the Congo, 2018 Guinea, 2016 Madagascar, 2018 Mozambique, 2019 Zambia, 2016 Common effect model	b) Odds Ratio 	OR 0.54 [(1.29 [0 2.14 [0. 0.55 [0 0.98 [0 0.14 [(1.48 [0] 0.44 [0 100 100 184F amon recrudescen	95%-Cl 0.14; 2.09] 0.02; 82.49] 03; 131.93] 04; 106.66] 02; 13.67] 09; 10.13] 0.01; 2.66] 0.06; 37.99] 0.16; 1.26]	crudescent in ents treated w



ASAQ. Odds ratio of Y184 among patients with recrudescent infection compared to the odds ratio of Y184 among patients who successfully cleared the infection. OR, odds ratio; CI, confidence interval.